Clinical Trial Update: Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of Cefiderocol for healthcare-associated pneumonia and hospital-acquired pneumonia has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthcare-associated Pneumonia
• Hospital-acquired Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Cefiderocol (cefiderocol)

Snippet

Sponsor: Shionogi | Conditions: Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP) | Phase 3 | Status: COMPLETED | Results posted: 2020-11-13